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PKC-d and -g, MEKK-1, MEK-6, MEK-3, and p38-d Are
Essential Mediators of the Response of Normal Human
Epidermal Keratinocytes to Differentiating Agents
Gautam Adhikary1, Yap Ching Chew1, E. Albert Reece1,3 and Richard L. Eckert1,2,3
Previous studies suggest that the novel protein kinase C (PKC) isoforms initiate a mitogen-activated protein
kinase (MAPK) signaling cascade that regulates keratinocyte differentiation. However, assigning these functions
has relied on treatment with pharmacologic inhibitors and/or manipulating kinase function using over-
expression of wild-type or dominant-negative kinases. As these methods are not highly specific, an obligatory
regulatory role for individual kinases has not been assigned. In this study, we use small interfering RNA
knockdown to study the role of individual PKC isoforms as regulators of keratinocyte differentiation induced by
the potent differentiating stimulus, 12-O-tetradecanoylphorbol-13-acetate (TPA). PKC-d knockdown reduces
TPA-activated involucrin promoter activity, nuclear activator protein-1 factor accumulation and binding to DNA,
and cell morphology change. Knockdown of PKC downstream targets, including MEKK-1, MEK-6, MEK-3, or p38-
d, indicates that these kinases are required for these responses. Additional studies indicate that knockdown of
PKC-Z inhibits TPA-dependent involucrin promoter activation. In contrast, knockdown of PKC-a (a classical PKC
isoform) or PKC-e (a novel isoform) does not inhibit these TPA-dependent responses. Further studies indicate
that PKC-d is required for calcium and green tea polyphenol-dependent regulation of end responses. These
findings are informative as they suggest an essential role for selected PKC and MAPK cascade enzymes in
mediating a range of end responses to a range of differentiation stimuli in keratinocytes.
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INTRODUCTION
The protein kinase C (PKC) kinases comprise a family of
enzymes that have a key role in regulating cell growth and
differentiation. PKC isoforms are classified into three groups
(Newton, 1997). The classical PKC forms (a, b, and g) are
calcium, phospholipid, and diacylglycerol dependent; the
novel PKCs (d, e, Z, and y) are activated by diacylglycerol
and phospholipids, but they do not respond directly to
calcium; and the atypical PKCs (z and l) are calcium and
diacylglycerol independent but undergo allosteric activation
(Nishizuka, 1992; Rosse et al., 2010). Epidermal keratino-
cytes express the PKC a, bII, d, e, Z, and z isoforms (Osada
et al., 1990; Dlugosz et al., 1992; Gherzi et al., 1992; Matsui
et al., 1992; Fisher et al., 1993; Shen et al., 2001; Hara et al.,
2005). The role of these isoforms has been studied in cultured
cells and animal models (Dlugosz and Yuspa, 1994; Acs
et al., 2000; Denning et al., 2000; Wheeler et al., 2002;
Verma et al., 2006; Aziz et al., 2009; Jerome-Morais et al.,
2009). A major ongoing effort is assigning specific functions
to individual PKC isoforms in regulating keratinocyte
proliferation, differentiation, and apoptosis. This is difficult,
as PKC isoforms are activated by common stimuli and share
common substrates. For example, the classical (a) and the
three novel (d, e, and Z) PKC isoforms expressed in
keratinocytes can be activated by the diacylglycerol analog,
12-O-tetradecanoylphorbol-13-acetate (TPA).
We and others have shown that the novel PKC isoforms
stimulate keratinocyte differentiation. This is evidenced by an
increase in differentiation-associated responses in the pre-
sence of increased nPKC expression (Eckert et al., 2004).
These nPKCs, in turn, activate mitogen-activated protein
kinase (MAPK) signaling, which results in increased nuclear
levels of activator protein-1 (AP-1), C/EBP, and Sp1, and
increased binding of these factors to target genes to increase
transcription (Efimova and Eckert, 2000; Efimova et al., 2002;
Eckert et al., 2004). PKC-d is the most potent of these
activators (Deucher et al., 2002) and its activity can be
inhibited by a PKC-d inhibitor, rottlerin (Efimova and Eckert,
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2000; Efimova et al., 2004; Zhu et al., 2008). A complicating
feature of these studies is that they rely on PKC isoform
overexpression, expression of dominant-negative kinases, or
the use of isoform-selective chemical inhibitors. Each of these
approaches has deficiencies, including the fact that over-
expression of a particular PKC isoform or a dominant-
negative form may influence the activity of other isoforms,
and the fact that most inhibitors are not specific for the target
kinase. An example is dominant-negative PKC-d that inhibits
PKC-d-, PKC-e- and PKC-Z-dependent human involucrin
(hINV) promoter activation (Efimova and Eckert, 2000). This
may be because dominant-negative PKC-d may compete for
common substrates with other PKC isoforms (Efimova and
Eckert, 2000). Thus, these studies, in spite of their utility, do
not adequately address the role of individual isoforms.
Previous studies also suggest that specific MAPK cascade
enzymes, including MAPK kinase kinase-1 (MEKK-1), MAPK/
extracellular signal-regulated kinase (ERK) kinase 3 (MEK-3),
and p38-d, are required for activation of differentiated gene
expression in keratinocytes (Efimova et al., 1998). On the
basis of these studies, we proposed that among the three p38
isoforms (a, b, and d) that are expressed at reasonable levels
in keratinocytes (Dashti et al., 2001a, b), p38-d has the
dominant role as a regulator of involucrin gene expression
(Efimova et al., 1998, 2003). However, here again, assigning
function relied on the use of wild-type and dominant-
negative kinase overexpression, and kinase inhibitors
(Efimova et al., 1998; Eckert et al., 2003, 2004, 2006).
In this study, as an alternative approach to avoid some of
these pitfalls, we use small interfering RNA (siRNA) to reduce
the level of individual PKC isoforms and individual MAPK
cascade kinases, and then challenge the cells with TPA, a
stable analog of diacylglycerol; calcium, a physiologic inducer
of keratinocyte differentiation; and (-)-epigallocatechin-3-
gallate (EGCG), a chemopreventive agent that stimulates
keratinocyte differentiation (Efimova et al., 1998; Efimova
and Eckert, 2000; Balasubramanian et al., 2002; Balasubra-
manian and Eckert, 2004). We examine the effect of reducing
individual kinase level on keratinocyte morphology, nuclear
transcription factor accumulation, and gene activation. These
studies suggest that PKC-d is a required mediator of the
keratinocyte response to several differentiating agents, and that
it controls a range of downstream biochemical and morpho-
logical end points. PKC-Z, and the MAPK cascade enzymes,
MEKK-1, MEK-6, and MEK-3, and p38-d MAPK are also
important. In contrast, PKC-a, PKC-e, p38-a, and p38-b seem
not to be the required mediators of these responses.
RESULTS
PKC-d is required for stimulus-dependent hINV promoter
activity
Previous studies show that overexpression of the novel PKC
isoforms, d, e, or Z, leads to increased hINV gene expression
(Efimova et al., 2002). To distinguish which of these isoforms
is mainly responsible for this regulation, we used siRNA-
mediated knockdown. We used TPA as a differentiation
stimulus, because TPA has a discrete mechanism of action, as
a diacylglycerol mimic (Kazanietz, 2005), and because it is a
strong inducer of morphological and biochemical differentia-
tion in keratinocytes (Welter et al., 1995). As shown in
Figure 1a and b, knockdown of PKC-d or PKC-Z reduces TPA-
dependent hINV promoter activation, but knockdown of
PKC-e is without effect. We also examined the effect of a
classical PKC isoform, PKC-a, and show that knockdown has
a minimal effect on promoter activity. Thus, among the novel
PKC isoforms, only PKC-d and PKC-Z are required as
mediators of TPA-dependent hINV promoter activation. In
contrast, basal promoter activity (absence of TPA treatment) is
not influenced by knockdown of the PKC isoforms.
PKC-d is required for nuclear accumulation of AP-1
transcription factors and change in cell morphology
PKC-d was selected for detailed study because its mechanism
of action in keratinocytes is heavily studied, it has a central
role in controlling keratinocyte processes (Deucher et al.,
2002; Wheeler et al., 2002; D’Costa and Denning, 2005;
D’Costa et al., 2005; Sitailo et al., 2006; Zhu et al., 2008),
and it is an effective regulator of involucrin gene expression
(Efimova et al., 2002, 2004). We first examined whether the
effect of reduced PKC-d may be mediated through effects on
expression of other PKC isoforms. As shown in Figure 1c,
PKC-d knockdown does not alter the level of other PKC
isoforms.
We next examined the effect of reduced PKC-d level on
TPA-dependent downstream responses. Activation of PKC
and MAPK kinase signaling has been shown to cause AP-1
factor movement into the nucleus in keratinocytes (Welter
et al., 1995). As shown in Figure 2a, TPA-dependent nuclear
accumulation of junB, c-fos, junD, and Fos-related antigen-1
(Fra-1) (Welter et al., 1995) is attenuated when PKC-d level is
reduced. A key question is whether this decrease leads to
reduced AP-1 factor interaction with binding sites on the
hINV promoter. Figure 2b is a gel mobility shift assay that
shows increased AP-1 factor DNA binding in response to TPA
treatment, and this increase is reduced in extracts from PKC-d
knockdown cells. This is specific binding, as it is competed
by radioinert AP-1 site oligonucleotide (Figure 2c).
We next explored whether PKC-d is required for other end
responses. TPA treatment is associated with cell elongation
and vesicle accumulation (Efimova and Eckert, 2000;
Efimova et al., 2002, 2003). Figure 3a shows that these
morphological changes are reduced by PKC-d knockdown.
For example, intracellular accumulation of vacuoles is
associated with TPA treatment. Untreated cells lack these
vacuoles, but approximately 45–50% of TPA-treated cells are
vacuole positive (arrows). In the presence of PKC-d siRNA,
TPA-dependent vacuole formation is reduced to o7% of
cells (Figure 3b). A similar reduction is observed for the
formation of elongated spindle-shaped cells. Thus, these
findings indicate that PKC-d is required for TPA-dependent
gene activation, nuclear AP-1 factor accumulation, and
morphological response. We also compared the role of PKCs
a, e, and Z in mediating TPA-dependent morphology change.
Figure 3b shows that PKC-Z knockdown partially reduces the
morphological response, but that PKC-a or PKC-e knockdown
does not restore normal morphology.
2018 Journal of Investigative Dermatology (2010), Volume 130
G Adhikary et al.
PKC-d and Keratinocyte Function
PKC-d is required for calcium- and EGCG-dependent regulation
We also explored whether PKC-d has a role in response to
other stimuli. These include calcium, a physiological inducer
of keratinocyte differentiation (Li et al., 1995; Denning et al.,
2000; Bikle et al., 2001, 2002), and EGCG, a chemopreven-
tive agent that is known to enhance keratinocyte differentia-
tion (Balasubramanian et al., 2002; Balasubramanian and
Eckert, 2004). Keratinocytes were treated with control or PKC
isoform-specific siRNA before challenge with calcium. This
resulted, as shown in Figure 4b, in the expected reduction in
PKC isoform level. Figure 4a shows that calcium treatment
produces a 4-fold increase in hINV promoter activity, and this
increase is completely inhibited when PKC-d level is
reduced. In contrast, knockdown of the other PKC isoforms
does not markedly attenuate the calcium-dependent increase
in promoter activity, except that in some experiments
knockdown of PKC-e did have a minimal effect on promoter
activity. Calcium treatment of keratinocytes also promotes
morphology change (Kimura et al., 2007). However, the
calcium-dependent change in cell morphology, observed in
cells grown in high calcium (0.6mM calcium) conditions, is
not inhibited by knockdown of PKCs a, d, e, or Z (not shown).
We have previously shown that EGCG increases hINV
promoter activity through activation of MAPK signaling
(Balasubramanian et al., 2002, 2005; Balasubramanian and
Eckert, 2004). We therefore examined whether PKC-d is
required for this response. As shown in Figure 5a, PKC-d
knockdown completely eliminates EGCG-dependent promo-
ter activation. Moreover, this is associated with a reduction in
EGCG-dependent movement of AP-1 factors (Fra-1, c-fos,
junB, and junD) into the nucleus (Figure 5c) and inhibition of
EGCG-associated morphology change (Figure 5b). We
also examined the effect of PKCs a, e, and Z siRNA on the
EGCG-dependent promoter activity, cell vacuole, and cell
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Figure 1. PKC-d and PKC-g are required for the TPA-dependent hINV promoter activation. (a) Knockdown of PKC isoform expression. Keratinocytes were
electroporated with 3 mg of control siRNA or siRNA specifying the indicated PKC isoforms per 1106 cells. Total cell extract was prepared at 48 hours after
electroporation and 25 mg of protein was electrophoresed for immunodetection of each PKC isoform. For purposes of convenience, we routinely measured PKC
levels at 48 hours after application of the siRNA; however, the levels remain reduced for up to 4 days (not shown). This experiment was repeated four times and
the siRNA-dependent reduction ranged as follows: PKC-a, 50–70%; PKC-d, 50–70%; PKC-e, 80–90%, and PKC-Z, 70–90%, as measured by densitometry.
(b) PKC-d is required for TPA-dependent promoter activation. At 48 hours after siRNA electroporation, cells were electroporated with 3 mg of endotoxin-free
pINV-2473. After an additional 6 hours, the cells were treated with 50 ngml–1 TPA and luciferase activity was assessed 18 hours later. The error bars represent
the mean±SD of a representative experiment. Similar results were observed in each of four separate experiments. The t-test analysis reveals that PKC-d and
PKC-Z siRNAs significantly suppress (Po0.01) TPA-stimulated promoter activity when compared with control siRNA, n¼ 4. The lesser reduction associated with
PKC-a siRNA treatment was not significant (Po0.98). (c) PKC-d knockdown does not influence the level of other PKC isoforms. Keratinocytes were
electroporated with 3 mg of control siRNA or PKC-d siRNA per 1 106 cells. Total cell extract was prepared at 48 hours after electroporation and 25 mg of protein
was electrophoresed for immunodetection of each PKC isoform. hINV, human involucrin; PKC, protein kinase C; siRNA, small interfering RNA; TPA, 12-O-
tetradecanoylphorbol-13-acetate.
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spindle-shaped formation, and found no effect (Figure 6),
suggesting that only the PKC-d isoform is required for these
responses.
MAP kinase signaling and keratinocyte response to TPA
treatment
PKC-d is thought to increase hINV promoter activity through
activation of a signaling cascade that includes MEKK-1, MEK-6,
and MEK-3 (Dashti et al., 2001a, b; Eckert et al., 2002). To
assess the role of these kinases, we used siRNA to reduce
MEKK-1, MEK-6, or MEK-3 level before challenge with
TPA. MEKK-1 knockdown produces a 50% reduction in
TPA-dependent hINV promoter activation (Figure 7a). MEK-6
knockdown produces an 80% reduction, and MEK-3 knock-
down completely suppresses activity. Figure 7b confirms that
the levels of MEKK-1, MEK-6, and MEK-3 are substantially
reduced by the siRNA treatment. We performed extensive
checks to assure siRNA specificity and in each case
confirmed that the reduction was target specific. As an
example, Figure 7c shows that siRNA knockdown of MEKK-1
does not alter MEK-3 or MEK-6 level. Similarly, MEK-3 or
MEK-6 knockdown did not influence the level of the other
kinases (not shown). Given that MEK-3 knockdown com-
pletely suppresses TPA-dependent hINV gene expression, we
further studied the effect of MEK-3 knockdown on nuclear
AP-1 factor level and cell morphology. As shown in
Figure 8a, MEK-3 knockdown reduces TPA-dependent
nuclear accumulation of Fra-1, junD, junB, and c-fos. Figure
8c shows that MEK-3 knockdown reduces TPA-dependent
increase in cell vacuole formation by 60% and spindle
shape by 50%. MEK-6 siRNA also partially attenuates the TPA
effect on cell morphology (30–40%), but is not as effective as
MEK-3 siRNA.
p38-d is required for TPA-dependent regulation
p38 MAPKs comprise a family of four structurally related
kinases, a, b, d, and g, that have been implicated in
regulating keratinocyte differentiation (Cobb, 1999; Chen
et al., 2001). Previous studies suggest that p38-d has an
important role in regulating involucrin gene expression
(Efimova et al., 2002, 2003). In the present experiments we
use siRNA-directed knockdown of p38-d to confirm this role.
Figure 9a shows the successful knockdown of p38 a, b, and d.
p38-g protein is not expressed in normal keratinocytes
(Dashti et al., 2001b; Eckert et al., 2004). Figure 9b shows
that p38-d knockdown results in reduced TPA-dependent
hINV promoter activity, but that reducing the level of the
p38-a or p38-b isoforms is without effect. As expected, as
p38-g is not readily detected in keratinocytes, p38-g siRNA
did not influence promoter activity. Figure 9c confirms that
the effect of p38-d knockdown is not because of an effect on
the level of other p38 isoforms. We next monitored the effect
of p38-d knockdown on TPA-dependent nuclear AP-1 factor
accumulation and morphological change. Figure 10a shows
that p38-d knockdown reduces the TPA-dependent accumu-
lation of junB, c-fos, junD, and Fra-1 in the nucleus. Figure
10b and c shows that p38-d knockdown partially reverses the
TPA effect on morphology. In addition, Figure 10c shows a
graphical analysis that indicates that knockdown of p38-a or
p38-b does not attenuate TPA-dependent changes in cell
morphology, but that p38-d knockdown partially reverses
these changes.
DISCUSSION
PKC-d is required for TPA-dependent responses in keratinocytes
Keratinocytes express six PKC isoforms, including PKCs a, bII,
d, e, Z, and z (Osada et al., 1990; Dlugosz et al., 1992;
Gherzi et al., 1992; Matsui et al., 1992; Fisher et al., 1993;
Shen et al., 2001; Hara et al., 2005). On the basis of their
primary sequence, response to stimuli, and unique cofactor
dependence, individual PKC isoforms are expected to have
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Figure 2. PKC-d knockdown reduces TPA-dependent nuclear accumulation
of AP-1 factors. Keratinocytes were electroporated with 3 mg of control or
PKC-d siRNA per 1 106 cells. After 24 hours, cells were treated with 0 or
50 ngml–1 TPA for an additional 48 hours before preparation of nuclear
extracts. (a) Nuclear extract (5 mg) was electrophoresed for immunological
detection of junB, c-fos, junD, and Fra-1. (b) Reduced PKC-d level is
associated with reduced TPA-induced AP-1 factor DNA binding.
Electrophoretic mobility shift assay was performed as outlined in the Materials
and Methods. The arrows indicate bands that bind to 32P-AP-1 double-
stranded oligonucleotide. (c) Nuclear extracts from cells treated with control
siRNA and 50 ngml–1 TPA were incubated with 32P-AP-1 in the presence of
10- or 50-fold excess of radioinert AP-1 double-stranded oligonucleotide
before non-denaturing gel electrophoresis. The arrows indicate migration of
the gel-shifted bands and FP indicates migration of the free probe. AP-1,
activator protein-1; Fra-1, Fos-related antigen-1; FP, migration of free probe;
NE, nuclear extract; PKC, protein kinase C; siRNA, small interfering RNA;
TPA, 12-O-tetradecanoylphorbol-13-acetate.
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different roles (Newton, 1997; Mellor and Parker, 1998).
However, individual PKC isoforms can be activated by
common ligands, use common substrates, and share common
downstream targets. For this reason, identifying the role of
individual PKC isoforms in keratinocytes is complicated. To
assign functions for these kinases, we previously used the
approach of overexpressing dominant-negative or wild-type
PKC isoforms and then monitored the effect on downstream
end points (Deucher et al., 2002; Efimova et al., 2002, 2004).
We have also used pharmacologic inhibitors of individual
PKC isoforms (Deucher et al., 2002; Efimova et al., 2002,
2004). These studies show that overexpressed novel PKC
60
50
40
30
20
10
0
20
15
10
5
0
– TPA
+ TPA
Control-
siRNA
PKCα-
siRNA
PKCδ-
siRNA
PKCε-
siRNA
PKCη-
siRNA
– TPA
+ TPA
Pe
rc
e
n
t o
f v
a
cu
o
la
te
d 
ce
lls
Pe
rc
e
n
t o
f e
lo
ng
at
ed
 s
pi
nd
le
-s
ha
pe
d 
ce
lls
Control-siRNA Control-siRNA
+TPA
PKCδ-siRNA PKCδ-siRNA
+ TPA
Figure 3. PKC-d knockdown reduces TPA effect on cell morphology. (a) Keratinocytes were electroporated with 3 mg of control or PKC-d siRNA per 1106
cells. After 24 hours, cells were treated with 0 or 50 ngml–1 TPA for an additional 48 hours before monitoring of cell morphology. Cells expressing normal PKC-d
level seem vacuolated and take on a spindle-shaped morphology, and this response is attenuated in PKC-d siRNA-treated cells. The arrows indicate vacuolated
cells. Bars¼ 25 mm in length. Phase-contrast images were obtained using an Olympus IX81 motorized inverted microscope (Hamburg, Germany) and a  20
objective. (b) Keratinocytes were electroporated with 3 mg siRNA encoding the indicated PKC isoform and treated with TPA as indicated above, and after an
additional 48 hours morphology was assessed. The plots were generated by determining the percentage of cells containing large intracellular vacuoles or
showing an elongated spindle shape (see photographs) out of a minimum of 100 cells on each of three slides. The results are expressed as the mean±SD. This
experiment is representative of four repeated experiments. The t-test analysis reveals that PKC-d and PKC-Z siRNAs significantly suppress (Po0.01) TPA-
stimulated cell shape change when compared with control siRNA, n¼4. PKC, protein kinase C; siRNA, small interfering RNA; TPA, 12-O-
tetradecanoylphorbol-13-acetate.
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isoforms (d, e, and Z) increase hINV protein and mRNA level,
and hINV promoter activity, and that treatment with chemical
inhibitors or dominant-negative PKC isoforms attenuates
these responses (Efimova et al., 1998, 2002; Efimova and
Eckert, 2000). However, analysis of this type of data is
complicated because of potential cross-effects and the fact
that the inhibitors are not necessarily specific.
PKC-d is required for TPA-mediated responses
To gain additional insight regarding which PKC isoforms are
required for stimulus-dependent regulation, we treated
keratinocytes with TPA in the presence of siRNA designed
to block expression of individual PKC isoforms. TPA was
selected because it is a potent inducer of keratinocyte
differentiation (Sharkey et al., 1984; Ashendel, 1985; Ono
et al., 1989; Nishizuka, 1992; Gschwendt et al., 1994), and is
an analog of the physiological regulator of classical and novel
PKC isoform, diacylglycerol, and thereby has a defined action
(Nishizuka, 1992). Treating human keratinocytes with TPA
increases cell differentiation; increases hINV gene expres-
sion, promoter activity, and mRNA level; and alters cell
morphology (Yaar et al., 1993; Welter and Eckert, 1995). Our
knockdown studies indicate that PKC-d is required for a range
of these TPA-induced responses, including AP-1 factor
accumulation in the nucleus, AP-1 factor binding to the hINV
promoter AP-1 site, hINV promoter activation, and morpho-
logy change. This is particularly interesting, because it
implicates PKC-d in a wide range of cell responses. Moreover,
our data suggest that we have only achieved a partial
(approximately 80%) reduction in PKC-d level. This suggests
that a threshold level of PKC-d may be required for response.
We also observed that PKC-Z knockdown attenuates TPA-
stimulated hINV promoter activity and morphology change.
Regarding hINV promoter activation, both PKC-Z and PKC-d
are required for this response. Given that this is the case, it is
not clear why, when PKC-d is reduced, the response is not
mediated by PKC-Z and vice versa. It is possible that two
independent pathways (one PKC-d dependent and the other
PKC-Z dependent) may be required to activate hINV gene
expression or that PKC-d and PKC-Z exist in a single common
pathway—perhaps through direct interaction. PKC-Z is also
required for the morphological response to TPA; however, it
seems to be less important than PKC-d with respect to
regulation of cell morphology. In contrast, PKC-a or PKC-e
knockdown does not attenuate any of the responses.
PKC-d is required for response to other agents
An important question is whether PKC-d is also a required
mediator of response to other agents that regulate keratino-
cyte differentiation. Our previous studies show that EGCG
treatment stimulates hINV promoter activity and cell
morphological change (Balasubramanian et al., 2002;
Balasubramanian and Eckert, 2004). These responses are
mediated through a MEKK-1, MEK-3, and p38-d pathway that
stimulates increased AP-1 factor level and AP-1 factor
binding to the hINV promoter, leading to increased hINV
gene expression (Balasubramanian et al., 2002). In this study
we show that PKC-d knockdown eliminates EGCG-depen-
dent responses, including hINV promoter activation, nuclear
AP-1 factor accumulation, and formation of elongated and
vacuolated cell morphology. These findings suggest that
PKC-d is required for keratinocyte response to two agents,
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Figure 4. PKC-d is required for the calcium-associated increase in hINV promoter activity. (a) Keratinocytes were electroporated with 3 mg of control siRNA or
the indicated PKC-specific siRNA per 1 106 cells. At 2 days after siRNA electroporation, the cells were trypsinized, collected by centrifugation, and
electroporated with 3 mg of endotoxin-free hINV promoter-luciferase reporter plasmid. After 6 hours, the cells were treated with KSFM (0.09mM calcium) or
KSFM containing 0.6mM calcium. After an additional 18 hours, the cells were harvested and extracts were assayed for luciferase activity. The results are
expressed as the mean±SD. This experiment is representative of three repeated experiments. The t-test analysis reveals that PKC-d siRNA significantly
suppresses (Po0.01) calcium-stimulated promoter activity below the activity observed with control siRNA, n¼3. (b) Keratinocytes were treated with siRNA as
indicated above and PKC isoform level was monitored after 48 hours. The experiment was repeated three times and the siRNA-dependent reduction in PKC
isoform level ranged as follows: PKC-a, 50–70%; PKC-d, 50–70%; PKC-e, 80–90%, and PKC-Z, 70–90%. hINV, human involucrin; KSFM, keratinocyte serum-
free medium; PKC, protein kinase C; siRNA, small interfering RNA.
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TPA and EGCG, which regulate differentiation. We also
monitored the effect of PKC-d knockdown on calcium-
dependent involucrin promoter activity. We and others have
shown that calcium treatment increases endogenous hINV
level and promoter activity (Bikle et al., 2001; Deucher et al.,
2002). These studies indicate that PKC-a inhibits (Deucher
et al., 2002) or activates (Bikle et al., 2001) hINV promoter
activity, and that PKC-d increases hINV protein level and
promoter activity (Efimova and Eckert, 2000). These knock-
down experiments indicate that PKC-d is required for the
calcium-dependent increase in hINV promoter activity, but
suggest that PKC-a is not required. Although PKC has been
reported to regulate desmosome formation (Sheu et al., 1989;
Amar et al., 1998; Kitajima et al., 1999; Alt et al., 2001), we
noted no effect of knockdown of any PKC isoform on
calcium-associated morphology change.
MEKK-1 and MEK-3 are required for TPA-dependent regulation
The MAPKs are important PKC targets. These kinases are
divided into families based on shared sequence homology
and function, and include ERK kinases (ERK1/2), p38 kinases
(p38 a, b, d, and g), and c-Jun N-terminal kinase (JNK) kinases
(JNK1/2) (Cobb, 1999; Cobb and Goldsmith, 2000; Raman
et al., 2007). MAPKs are regulated by a three-kinase module
that includes a MAPK kinase kinase (MAPKKK), a MAPK
kinase (MAPKK), and a MAPK (Chang and Karin, 2001; Eckert
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Figure 5. PKC-d is required for the EGCG-dependent hINV promoter activity, nuclear AP-1 factor accumulation, and morphology change. (a) Keratinocytes
were electroporated with 3 mg of control or PKC-d specific siRNA per 1 106 cells. At 48 hours after siRNA electroporation, cells were electroporated with 3 mg
of endotoxin-free pINV-2473. After an additional 6 hours, the cells were treated with 0–40 mM EGCG (left panel) or 50 ngml–1 TPA (right panel) and luciferase
activity was assessed 18hours later. The results are expressed as the mean±SD. The t-test analysis reveals that PKC-d siRNA significantly suppresses 20 and
40mM EGCG-dependent promoter activity (Po0.01) below the activity observed with control siRNA, n¼3. (b) PKC-d is required for EGCG-dependent
morphological change. Cells expressing normal PKC-d levels show a spindle-like shape and accumulate intracellular vacuoles, a response that is attenuated in
PKC-d-knockdown cells. The plots were generated by determining the percentage of cells containing large intracellular vacuoles or showing an elongated
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siRNA, n¼3. Bar¼ 25 mm. (c) PKC-d is required for EGCG-dependent nuclear accumulation of AP-1 factors. Nuclear extract (5 mg), prepared from cells treated
with 3 mg of control or PKC-d siRNA for 48 hours, was electrophoresed and nuclear levels of Fra-1, c-fos, junB, and junD were detected by immunoblot. AP-1,
activator protein-1; EGCG, (-)-epigallocatechin-3-gallate; Fra-1, Fos-related antigen-1; PKC, protein kinase C; siRNA, small interfering RNA; TPA, 12-O-
tetradecanoylphorbol-13-acetate.
www.jidonline.org 2023
G Adhikary et al.
PKC-d and Keratinocyte Function
et al., 2003; D’Costa and Denning, 2005). These kinases are
important regulators of keratinocyte proliferation, differentia-
tion, and survival. In general, activation of p38-d MAPK
increases keratinocyte differentiation, whereas activation of
ERK1/2 promotes survival (Eckert et al., 2002, 2003). Our
previous studies, using overexpression of wild-type and
dominant-negative kinases and pharmacologic inhibitors,
suggest a role for MEKK-1, MEK-6, and MEK-3 in regulating
hINV gene expression (Efimova et al., 1998, 2003; Eckert
et al., 2002; Kraft et al., 2007). These studies show that
treatment with TPA, overexpression of activated Ras
(RasG12V), or overexpression of wild-type MEKK-1 increase
hINV gene expression. Moreover, these events are inhibited
by dominant-negative MEKK-1 (Efimova et al., 1998).
However, these studies are complicated by the fact that they
rely on overexpression. This study provides evidence that
MEKK-1 is important in this pathway, as knockdown of
MEKK-1 attenuates hINV promoter activation in response to
TPA treatment. Thus, MEKK-1 seems to be a key part of the
TPA-triggered signaling cascade that leads to increased hINV
promoter activity. It will be interesting in future studies to
examine the role of other MEKK kinases (e.g., MEKK-2,
MEKK-3, etc.) in this regulation, as various studies suggest a
role for these kinases as alternate upstream activators of p38
MAPK (Uhlik et al., 2004).
Our previous study shows that dominant-negative MEK-3
inhibits TPA-dependent hINV promoter activity (Efimova
et al., 1998). Our present MEK-3 knockdown experiments
confirm a required role for MEK-3 in TPA-dependent hINV
promoter activation. We also show a substantial reduction in
TPA-dependent hINV promoter activity in MEK-6 knockdown
cells. Knocking down MEK-3 or MEK-6 also reduces TPA-
dependent morphology change. These results suggest that
both MEK-3 and MEK-6 have a role in activating p38-d that
leads to downstream changes in gene expression and cell
morphology. It is interesting that knockdown of either MEK-3
or MEK-6 reduces hINV promoter response. This is surprising
because MEK-3 could be expected to compensate for the loss
of MEK-6 and vice versa. Such a finding suggests that these
kinases operate in parallel essential signaling cascades or are
part of the same signaling cascade.
p38-d mediates TPA-associated responses
p38 MAPKs respond to a wide range of extracellular cues,
particularly cellular stressors such as UV radiation, osmotic
shock, hypoxia, pro-inflammatory cytokines, and less often
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Figure 6. PKCs a, e, and g are not required for EGCG-dependent hINV promoter activity or morphology change. (a) PKC a, e, and Z isoforms are not
required for EGCG-stimulated hINV promoter activity. Keratinocytes were electroporated with 3 mg of control or PKC-d-specific siRNA per 1 106 cells.
At 48 hours after siRNA electroporation, cells were electroporated with 3mg of endotoxin-free pINV-2473. After an additional 6 hours, the cells were treated with
40mM EGCG and luciferase activity was assessed 18 hours later. The results are expressed as the mean±SD. This experiment is representative of four repeated
experiments. (b) PKC a, e, and Z isoforms are not required for EGCG-dependent morphology change. Keratinocytes were electroporated with siRNA encoding
the indicated PKC isoform and treated with EGCG for 48 hours as indicated above and morphology was assessed. The plots were generated by determining
the percentage of cells containing large intracellular vacuoles or showing an elongated spindle-shaped morphology out of a minimum of 100 cells on each
of three slides. The results are expressed as the mean±SD. This experiment is representative of four repeated experiments. EGCG, (-)-epigallocatechin-3-gallate;
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growth factors. There are four p38 family members (a, b, d,
and g), and among them p38-a is the most widely studied
(Raman et al., 2007). p38 isoforms are activated by MEK-3
and MEK-6 through dual phosphorylation of p38 active motif
serine and threonine residues. It is interesting that although
p38 isoforms are 40% identical to other MAPKs (ERK1/2,
etc.), they share only approximately 60% identity among
themselves. This suggests diverse functions. p38-a and p38-b
are ubiquitously expressed and are inhibited by pyridinyl
imidazole compounds, whereas expression of p38-d and
p38-g are not inhibited by these agents and have a more
limited tissue distribution.
Keratinocytes express p38 a, b, and d (Dashti et al.,
2001a, b), and qPCR studies reveal that the mRNA encoding
these isoforms is present in the following ratio: p38-a 1.0,
p38-b 0.5, p38-d 1.0, and p38g 0.05 (not shown). Although
p38-g-encoding RNA is present, the level is low and, as
previously described, the p38-g protein is not detected
(Efimova et al., 2003, 2004; Kraft et al., 2007). Thus, the
present studies focus on p38 a, b, and d. Previous studies
suggest that p38-d activation is associated with increased
hINV promoter activity and keratinocyte differentiation
(Efimova et al., 2003, 2004; Kraft et al., 2007). This regulation
involves a p38-d-ERK1/2 complex, and overexpressed
p38-d inhibits ERK1/2 activity without reducing ERK1/2 level,
suggesting that p38-d may directly suppress ERK1/2 function
(Eckert et al., 2002, 2003). We were able to rule out a
role for p38-a or p38-b based on inhibitor studies (Efimova
et al., 1998). We also used dominant-negative p38-a as a tool
to study the response and showed that dominant-negative
p38-a inhibits hINV promoter activation, in response to
treatment with TPA or because of overexpression of
constitutive active Ras (RasG12V) or wild-type MEKK-1
(Efimova et al., 1998). However, this analysis is problematic,
as dominant-negative p38-a may inhibit the function of all
p38 isoforms. The present knockdown studies provide
additional clarity, as we show that p38-d knockdown
suppresses TPA-dependent increase in hINV promoter
activity and nuclear accumulation of AP-1 factors, but that
p38-a and p38-b knockdown does not attenuate these
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responses. These findings suggest that p38-d is an important
mediator of these events.
In summary, our findings suggest that PKC-d, and to a
lesser extent, PKC-Z, are key regulators of the keratinocyte
response to TPA, EGCG, and calcium. Moreover, down-
stream kinases, including MEKK-1, MEK-6, MEK-3, and p38-
d, are also important mediators in this signaling cascade, but
p38-a and p38-b do not seem to have a role. A striking
finding is that these kinases are required mediators for a range
of responses, including gene activation events, nuclear
transcription factor accumulation and binding to target sites,
and morphology change, and are also required for response
to a range of agents (calcium, green tea, and phorbol ester).
Taken together, these findings suggest that these enzymes are
central controllers of normal keratinocyte function.
MATERIALS AND METHODS
Chemicals and Reagents
Keratinocyte serum-free medium and trypsin was purchased from
Invitrogen (Carlsbad, CA). Phorbol ester (TPA) and dimethylsulfoxide
were obtained from Sigma-Aldrich (St Louis, MO). pGL2-basic
plasmid and the chemiluminescent luciferase assay system were
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Figure 8. MEK-3 knockdown reduces TPA-dependent nuclear AP-1 factor accumulation and morphological response. Keratinocytes were electroporated with
3mg of control or MEK-3 siRNA per 1 106 cells. After 24 hours, cells were treated with 50 ngml–1 TPA for an additional 48 hours. (a) Nuclear extract (5 mg) was
electrophoresed for detection of junB, c-fos, junD, and Fra-1. (b) MEK-3 siRNA reduces the effect of TPA treatment on keratinocyte morphology. Keratinocytes
were electroporated with 3 mg of MEK-3 siRNA and then treated for an additional 48 hours with TPA before assessment of morphology. Bars¼ 25mm. The arrows
indicate cells containing large intracellular vacuoles. (c) Effect of MEK-6 and MEK-3 knockdown on TPA-induced keratinocyte morphology change.
Keratinocytes were electroporated with 3 mg of specific siRNA and then treated with 50 ngml–1 TPA for 48 hours before assessing the effect on morphology. The
plots were generated by determining the percentage of cells containing large intracellular vacuoles or showing an elongated spindle shape (see pictures) out of a
minimum of 100 cells on each of three slides. The results are expressed as the mean±SD. MEK-6 (Po0.05) and MEK-3 (Po0.01) siRNAs significantly suppress
TPA-stimulated morphology change when compared with control siRNA, n¼3. AP-1, activator protein-1; Fra-1, Fos-related antigen-1; MEK, MAPK/ERK kinase;
siRNA, small interfering RNA; TPA, 12-O-tetradecanoylphorbol-13-acetate.
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purchased from Promega (Madison, WI), and chemiluminescence
was measured using a Berthold luminometer (Wildbad, Germany).
The involucrin-specific polyclonal antibody was previously
described (LaCelle et al., 1998). Anti-b-actin was purchased from
Sigma-Aldrich (A5441). Rabbit polyclonal antibodies specifying
c-fos (sc-52X), fosB (sc-48X), Fra-1 (sc-605X) JunB (sc-46X) c-jun
(sc-1694X), and JunD (sc-74X) were from Santa Cruz Biotechnology
(Santa Cruz, CA). Antibodies for PKC-a (sc-208), PKC-d (sc-937),
PKC-e (sc-214), PKC-z (sc-7262), PKC-Z (sc-215), MEKK-1 (sc-252),
MEK-6 (sc-6073), MEK3 (sc-960), p38-a (sc-7972), p38-b (sc-6176),
p38-g (sc-33690), and p38-d (sc-7587) were obtained from Santa
Cruz Biotechnology. Peroxidase-conjugated anti-mouse IgG
(NXA931) and peroxidase-conjugated anti-rabbit IgG (NA934V)
were obtained from GE Healthcare (Buckinghamshire, UK). The
hINV gene expression reporter plasmids were previously described
(Welter et al., 1996; Efimova et al., 1998). Gene-specific siRNA were
purchased from Santa Cruz as follows: control (sc-37007), PKC-a
(sc-36243), PKC-d (sc-36253), PKC-e (sc-36251), PKC-Z (sc-44019),
MEKK-I (sc-35898), MEK-6 (sc-35913), MEK-3 (sc-35907), p38-a
(sc-29433), p38-b (sc-39116), p38-d (sc-36456), and p38-g
(sc-39118). Additional siRNA, including PKC-d (J-003524–08), p38-b
(J-003972–12), and p38-d (J-003591–09), were from Dharmacon
(Lafayette, CO). EGCG was obtained from Sigma.
Immunological methods
For immunoblot, equivalent amounts of protein was electrophoresed
on denaturing and reducing 8% polyacrylamide gels and transferred
to nitrocellulose membrane. The membrane was blocked by 5%
nonfat dry milk and then incubated with appropriate primary and
secondary antibody. Antibody binding was visualized using chemi-
luminescence detection reagents.
Keratinocyte electroporation
Keratinocytes, prepared from human foreskin samples, were electro-
porated with siRNA or plasmids using the Amaxa electroporator and
the VPD-1002 nucleofection kit (Amaxa, Cologne, Germany).
For electroporation, keratinocytes were harvested with trypsin and
replated 1 day before use. On the day of electroporation, 1 106 of
the replated cells were harvested with trypsin and resuspended in
keratinocyte serum-free medium. The cells are collected at
2,000 g, washed with 1ml of sterile phosphate-buffered saline
(pH 7.5), and suspended in 100ml of keratinocyte nucleofection
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Figure 9. p38-d is required for the TPA-dependent hINV promoter activation. (a) Knockdown of p38 isoform expression. Keratinocytes were electroporated
with 3mg of control siRNA or siRNA encoding the indicated p38 isoforms per 1106 cells. Total cell extract was prepared at 48 hours after electroporation
and 25 mg protein was electrophoresed for immunodetection of each p38 isoform. This experiment was repeated four times and the siRNA-dependent
reduction in level ranged as follows: p38-a, 80–90%; p38-b, 70–90%; and p38-d, 80–90%, as measured by densitometry. (b) p38-d is required for
TPA-dependent hINV promoter activation. At 48 hours after siRNA electroporation, cells were electroporated with 3 mg of endotoxin-free pINV-2473.
After an additional 6 hours, the cells were treated with 50 ngml–1 TPA and luciferase activity was assessed 18 hours later. The results are expressed as the
mean±SD. p38-d siRNA significantly suppresses (Po0.01) TPA-stimulated promoter activity below the activity observed with control siRNA, n¼ 3.
(c) p38-d knockdown does not influence the level of other p38 isoforms. Keratinocytes were electroporated with 3 mg of control or p38-d isoform-specific siRNA
per 1 106 cells. Total cell extract was prepared at 48 hours after electroporation and 25mg of protein was electrophoresed for immunodetection of each
p38 isoform. This experiment was repeated twice with similar results. hINV, human involucrin; siRNA, small interfering RNA; TPA, 12-O-tetradecanoylphorbol-
13-acetate.
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solution. The cell suspension, which included 3 mg of gene-specific
siRNA, was mixed by gentle up and down pipetting and electro-
porated using the T-018 settings. Warm keratinocyte serum-free
medium (500 ml) was added and the suspension was transferred to a
9.6 cm2 cell culture plate containing 1.5ml of keratinocyte serum-
free medium. Reduced level of the siRNA targeted protein was
confirmed by immunoblot. In all cases, maximal reduction was
observed by 48hours and the reduced level was maintained until at
least 96 hours.
Promoter activity
At 2 days after siRNA electroporation, cells were trypsinized,
collected by centrifugation, and electroporated with 3mg of
endotoxin-free hINV promoter-luciferase reporter plasmid (pINV-
2473) (Welter et al., 1995). After 6 hours, the cells were treated with
50 ngml–1 TPA and after an additional 18 hours the cells were
washed with phosphate-buffered saline (pH 7.5) and scraped into
120ml of cell lysis buffer before assay of luciferase activity. All assays
were performed in duplicate, and each experiment was repeated a
minimum of three times. Luciferase activity was normalized as
previously described (Efimova et al., 2002).
Nuclear extract preparation and gel mobility shift assay
Keratinocytes were electroporated with 3mg of siRNA and plated in
58 cm2 surface area (100mm) dishes. After 24 hours, cells were
incubated with EGCG (0–40 mM) or TPA (0–50 ngml–1) for 48 hours.
The cells were then washed with phosphate-buffered saline and
nuclear extract was prepared (Welter et al., 1995). Transcription
factors binding to the AP-1 site was assayed by gel electrophoretic
mobility shift (Welter et al., 1995). Nuclear extract protein (3 mg) was
incubated for 25minutes at 25 1C in a total volume of 20 ml
containing 20mM HEPES (pH 7.5), 10% glycerol, 50mM KCl, 2mM
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Figure 10. p38-d knockdown affects nuclear AP-1 factor level and cell morphology. (a) p38-d is required for TPA-dependent nuclear localization of AP-1
factors. Keratinocytes were electroporated with 3 mg of control or p38-d siRNA per 1 106 cells. After 24 hours, cells were treated with 50 ngml–1 TPA for an
additional 48 hours. Nuclear extract (5 mg) was electrophoresed for detection of junB, c-fos, junD, and Fra-1. (b) p38-d knockdown reduces the effect of TPA on
keratinocyte morphology. Keratinocytes were electroporated with 3 mg of control or p38-d siRNA per 1 106 cells. After 24 hours, cells were treated with
50 ngml–1 TPA for an additional 48 hours. Bars¼25 mm. The arrows indicate vacuolated cells. (c) p38-a and p38-b knockdown does not reduce the effect of TPA
on keratinocyte morphology. Keratinocytes were treated with siRNA and TPA as indicated above before assessment of cell morphology. The plots were
generated by determining the percentage of cells containing large intracellular vacuoles or showing an elongated spindle-shaped morphology out of a minimum
of 100 cells on each of three slides. The results are expressed as the mean±SD. p38-d siRNA significantly suppresses (Po0.01) TPA-stimulated morphology
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MgCl2, 0.5mM EDTA, 0.5mM dithiothreitol, 1 mgml
–1 poly (dI-dC),
0.1mgml–1 bovine serum albumin, and 50,000 c.p.m. of 32P-labeled
AP-1 site (50-CGCTTGATGAGTCAGCCGGAA-30) (Welter et al.,
1995). The bold nucleotides indicate the consensus AP-1 DNA-
binding site. For gel mobility supershift assay, AP-1 factor-specific
antibodies (2 mg) were added to the reaction mixture and incubated
at 4 1C for 45minutes. The 32P-labeled AP-1 probe was then added
and the mixture was incubated for 30minutes at room temperature.
Protein–DNA complexes were then separated in a non-denaturing
6% polyacrylamide gel and band migration was detected by
autoradiography.
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